p53 and c-erbB-2 protein expression was immunohistochemically examined in a consecutive series of 49 primary breast cancer patients with a 10-year follow-up. The study was performed on paraffin sections using the monoclonal antibodies DO7 and CBE1; the former recognizes both the wild-type and the mutant p53 forms, the latter recognizes the external domain of the transmembrane c-erbB-2 protein. Positive staining was expressed in 12.2% and 16.3% of cases for p53 and c-erbB-2 proteins, respectively. The results were related to clinicopathological parameters by the chi 2 test. A significant correlation was found between positive c-erbB-2 immunostaining and poor survival (P = 0.04) and between p53 and c-erbB-2 overexpression (P = 0.003); this co-overexpression correlated well with a poor clinical outcome (P = 0.040). From our results, we may speculate that simultaneous expression of p53 and c-erbB-2 oncoproteins could be a critical event in breast tumor progression, and therefore, of prognostic value to identify patients at high risk.

Value of c-erbB-2 and p53 oncoprotein co-overexpression in human breast cancer / A., Barbati; Cosmi, Ermelando; A., Sidoni; P., Collini; Porpora, Maria Grazia; I., Ferri; M., Luthy; V., Lauro; E., Bucciarelli. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - STAMPA. - 17:1A(1997), pp. 401-406.

Value of c-erbB-2 and p53 oncoprotein co-overexpression in human breast cancer.

COSMI, Ermelando;PORPORA, Maria Grazia;
1997

Abstract

p53 and c-erbB-2 protein expression was immunohistochemically examined in a consecutive series of 49 primary breast cancer patients with a 10-year follow-up. The study was performed on paraffin sections using the monoclonal antibodies DO7 and CBE1; the former recognizes both the wild-type and the mutant p53 forms, the latter recognizes the external domain of the transmembrane c-erbB-2 protein. Positive staining was expressed in 12.2% and 16.3% of cases for p53 and c-erbB-2 proteins, respectively. The results were related to clinicopathological parameters by the chi 2 test. A significant correlation was found between positive c-erbB-2 immunostaining and poor survival (P = 0.04) and between p53 and c-erbB-2 overexpression (P = 0.003); this co-overexpression correlated well with a poor clinical outcome (P = 0.040). From our results, we may speculate that simultaneous expression of p53 and c-erbB-2 oncoproteins could be a critical event in breast tumor progression, and therefore, of prognostic value to identify patients at high risk.
1997
breast cancer; c-erbb-2; p53
01 Pubblicazione su rivista::01a Articolo in rivista
Value of c-erbB-2 and p53 oncoprotein co-overexpression in human breast cancer / A., Barbati; Cosmi, Ermelando; A., Sidoni; P., Collini; Porpora, Maria Grazia; I., Ferri; M., Luthy; V., Lauro; E., Bucciarelli. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - STAMPA. - 17:1A(1997), pp. 401-406.
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/246089
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 22
social impact